3 results
Scar volume and POSAS score will be measured in the Verapamil group, these will be compared to the scar volume and POSAS score in the Kenacort+Verapamil group and the Kenacort group. In addition, complications/ adverse effects will be reported.
Primary objectiveTo compare the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine.Secondary objectivesEfficacy- To compare the objective response of subjects treated with either pimasertib or dacarbazine.- To…
The primary objective of the study is to compare the PFS of SPd versus EloPd in patients with MM who have received 1 to 4 prior anti-MM lines of therapy and never received pomalidomide, selinexor, or elotuzumab. Patients must have had prior…